BioCentury
ARTICLE | Company News

Sept. 6 Company Quick Takes: Soliris patents denied; plus Novartis, Roche, Lilly and Boehringer

September 6, 2019 10:08 PM UTC

EU patent office denies Alexion two Soliris patents
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) disclosed in a Sept. 5 SEC filing that the European Patent office declined to grant two Soliris eculizumab patents: one covering pharmaceutical compositions and the other covering composition of matter. The company, which took a hit Aug. 30 when the U.S. Patent and Trademark Office said it will review the validity of three Soliris patents based on an inter partes review challenge from Amgen Inc. (NASDAQ:AMGN), is considering appealing the EU decision (see "Alexion Sinks as PTAB Institutes Review").

Breakthrough for Novartis' NSCLC candidate
Ahead of an expected NDA submission next quarter, FDA granted breakthrough therapy designation to capmatinib from Novartis AG (NYSE:NVS; SIX:NOVN) for first-line treatment of metastatic non-small cell lung cancer harboring c-MET (c-Met receptor tyrosine kinase; MET; HGFR) exon 14 skipping mutations...